Rising Price Complaints Prompt Renewed China Probes
This article was originally published in PharmAsia News
Pfizer is reportedly among a clutch of drug makers said to have been summoned to provide information in China's latest investigation of drug prices, which has apparently been prompted by rising public complaints over medicine costs. Chinese regulators could also impose hefty new fines on multinationals if they refuse to provide relevant materials or information, under a draft of revised antitrust regulation.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.